∼20–40% of patients with IBD in Western countries are obese
Premorbid obesity, in particular visceral adiposity, might increase the risk of developing Crohn's disease
Obesity might contribute to the pathogenesis of IBD through dysbiosis, mucosal barrier dysfunction with bacterial translocation and activation of adipocytes
Risk of complications, such as surgery, hospitalization and infection, might be increased in patients with IBD who are obese
Obesity is associated with rapid clearance of biologic agents, resulting in low trough concentrations, and could result in suboptimal response to biologics
Treating obesity could be a potential adjunct therapeutic target in patients with IBD who are obese
Incidence of IBD is rising in parallel with overweight and obesity. Contrary to conventional belief, about 15–40% of patients with IBD are obese, which might contribute to the development of IBD. Findings from cross-sectional and retrospective cohort studies are conflicting on the effect of obesity on natural history and course of IBD. Most studies are limited by small sample size, low event rates, non-validated assessment of disease activity and lack robust longitudinal follow-up and have incomplete adjustment for confounding factors. The effect of obesity on the efficacy of IBD-related therapy remains to be studied, though data from other autoimmune diseases suggests that obesity results in suboptimal response to therapy, potentially by promoting rapid clearance of biologic agents leading to low trough concentrations. These data provide a rationale for using weight loss interventions as adjunctive therapy in patients with IBD who are obese. Obesity also makes colorectal surgery technically challenging and might increase the risk of perioperative complications. In this Review, we highlight the existing literature on the epidemiology of obesity in IBD, discuss its plausible role in disease pathogenesis and effect on disease course and treatment response, and identify high-priority areas of future research.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766–781 (2014).
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W. & Dietz, W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 28, w822–w831 (2009).
Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54 (2012).
Ng, S. C. et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology 150, 86–95. e3 (2016).
Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720–727 (2015).
Qin, B. et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res. Ther. 17, 86 (2015).
Sterry, W., Strober, B. E., Menter, A. & International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br. J. Dermatol. 157, 649–655 (2007).
Flores, A., Burstein, E., Cipher, D. J. & Feagins, L. A. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig. Dis. Sci. 60, 2436–2445 (2015).
Long, M. D. et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm. Bowel Dis. 17, 2162–2168 (2011).
Pringle, P. L. et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn's disease. Inflamm. Bowel Dis. 21, 2304–2310 (2015).
Mendall, M. A., Gunasekera, A. V., John, B. J. & Kumar, D. Is obesity a risk factor for Crohn's disease? Dig. Dis. Sci. 56, 837–844 (2011).
Seminerio, J. L. et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 21, 2857–2863 (2015).
Nic Suibhne, T. et al. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J. Crohns Colitis 7, e241–e248 (2013).
Stabroth-Akil, D., Leifeld, L., Pfutzer, R., Morgenstern, J. & Kruis, W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int. J. Colorectal Dis. 30, 237–242 (2015).
Steed, H., Walsh, S. & Reynolds, N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes. Facts 2, 370–372 (2009).
Kugathasan, S. et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J. Pediatr. 151, 523–527 (2007).
Blain, A. et al. Crohn's disease clinical course and severity in obese patients. Clin. Nutr. 21, 51–57 (2002).
Moran, G. W., Dubeau, M.-F., Kaplan, G. G., Panaccione, R. & Ghosh, S. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm. Bowel Dis. 19, 2949–2956 (2013).
Khalili, H. et al. Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 21, 361–368 (2015).
Harpsoe, M. C. et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int. J. Epidemiol. 43, 843–855 (2014).
Chan, S. S. M. et al. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am. J. Gastroenterol. 108, 575–582 (2013).
Hemminki, K., Li, X., Sundquist, J. & Sundquist, K. Risk of asthma and autoimmune diseases and related conditions in patients hospitalized for obesity. Ann. Med. 44, 289–295 (2012).
Kredel, L. I. & Siegmund, B. Adipose-tissue and intestinal inflammation — visceral obesity and creeping fat. Front. Immunol. 5, 462 (2014).
Uko, V. et al. Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease. Inflamm. Bowel Dis. 20, 2286–2291 (2014).
Khalili, H. et al. Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ 347, f6633 (2013).
Bilski, J., Brzozowski, B., Mazur-Bialy, A., Sliwowski, Z. & Brzozowski, T. The role of physical exercise in inflammatory bowel disease. Biomed. Res. Int. 2014, 429031 (2014).
Zietek, T. & Rath, E. Inflammation meets metabolic disease: gut feeling mediated by GLP-1. Front. Immunol. 7, 154 (2016).
Karmiris, K. et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis. 12, 100–105 (2006).
Tian, J., Venn, A., Otahal, P. & Gall, S. The association between quitting smoking and weight gain: a systemic review and meta-analysis of prospective cohort studies. Obes. Rev. 16, 883–901 (2015).
Berthon, B. S., MacDonald-Wicks, L. K. & Wood, L. G. A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr. Res. 34, 179–190 (2014).
Wung, P. K. et al. Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum. 59, 746–753 (2008).
Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin resistance. Cell Metab. 23, 413–426 (2016).
Balistreri, C. R., Caruso, C. & Candore, G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010, 802078 (2010).
Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219–246 (2010).
Kredel, L., Batra, A. & Siegmund, B. Role of fat and adipokines in intestinal inflammation. Curr. Opin. Gastroenterol. 30, 559–565 (2014).
Zulian, A. et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 61, 86–94 (2012).
Batra, A., Zeitz, M. & Siegmund, B. Adipokine signaling in inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1897–1905 (2009).
Dulai, P. S., Levesque, B. G., Feagan, B. G., D'Haens, G. & Sandborn, W. J. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest. Endosc. 82, 246–255 (2015).
Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85–97 (2011).
Trayhurn, P. & Wood, I. S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92, 347–355 (2004).
Schaffler, A., Scholmerich, J. & Salzberger, B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 28, 393–399 (2007).
Stroh, T. et al. Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. J. Immunol. 181, 3620–3627 (2008).
Charriere, G. et al. Preadipocyte conversion to macrophage: evidence of plasticity. J. Biol. Chem. 278, 9850–9855 (2003).
Desreumaux, P. et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 117, 73–81 (1999).
Paul, G. et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm. Bowel Dis. 12, 471–477 (2006).
La Cava, A. & Matarese, G. The weight of leptin in immunity. Nat. Rev. Immunol. 4, 371–379 (2004).
Batra, A. et al. Leptin: a critical regulator of CD4+ T-cell polarization in vitro and in vivo. Endocrinology 151, 56–62 (2010).
Siegmund, B., Lehr, H. A. & Fantuzzi, G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 122, 2011–2025 (2002).
Nishihara, T. et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology 131, 853–861 (2006).
Fayad, R. et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 132, 601–614 (2007).
Ohashi, K. et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem. 285, 6153–6160 (2010).
Ogunwobi, O. O. & Beales, I. L. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul. Pept. 134, 105–113 (2006).
Schaffler, A. & Scholmerich, J. The role of adiponectin in inflammatory gastrointestinal diseases. Gut 58, 317–322 (2009).
Bokarewa, M., Nagaev, I., Dahlberg, L., Smith, U. & Tarkowski, A. Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174, 5789–5795 (2005).
Konrad, A. et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur. J. Gastroenterol. Hepatol. 19, 1070–1074 (2007).
Sideri, A. et al. Effects of obesity on severity of colitis and cytokine expression in mouse mesenteric fat. Potential role of adiponectin receptor 1. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G591–G604 (2015).
Zulian, A. et al. Differences in visceral fat and fat bacterial colonization between ulcerative colitis and Crohn's disease. An in vivo and in vitro study. PLoS ONE 8, e78495 (2013).
Peyrin-Biroulet, L. et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 61, 78–85 (2012).
Yamamoto, K. et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 54, 789–796 (2005).
Sheehan, A. L., Warren, B. F., Gear, M. W. & Shepherd, N. A. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br. J. Surg. 79, 955–958 (1992).
Kim, A. Dysbiosis: a review highlighting obesity and inflammatory bowel disease. J. Clin. Gastroenterol. 49 (Suppl. 1), S20–S24 (2015).
Worthington, J. J. The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease. Biochem. Soc. Trans. 43, 727–733 (2015).
Cani, P. D., Everard, A. & Duparc, T. Gut microbiota, enteroendocrine functions and metabolism. Curr. Opin. Pharmacol. 13, 935–940 (2013).
Leone, V. A., Cham, C. M. & Chang, E. B. Diet, gut microbes, and genetics in immune function: can we leverage our current knowledge to achieve better outcomes in inflammatory bowel diseases? Curr. Opin. Immunol. 31, 16–23 (2014).
Lee, D. et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology 148, 1087–1106 (2015).
Gruber, L. et al. High fat diet accelerates pathogenesis of murine Crohn's disease-like ileitis independently of obesity. PLoS ONE 8, e71661 (2013).
Hou, J. K., Abraham, B. & El-Serag, H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am. J. Gastroenterol. 106, 563–573 (2011).
Rioux, J. D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39, 596–604 (2007).
Sakiyama, T., Fujita, H. & Tsubouchi, H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease. Inflamm. Bowel Dis. 14, 310–317 (2008).
Harrison, E., Lal, S. & McLaughlin, J. T. Enteroendocrine cells in gastrointestinal pathophysiology. Curr. Opin. Pharmacol. 13, 941–945 (2013).
Qi, K. K., Wu, J., Wan, J., Men, X. M. & Xu, Z. W. Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis. Peptides 52, 11–18 (2014).
Blonski, W., Buchner, A. M., Aberra, F. & Lichtenstein, G. Teduglutide in Crohn's disease. Expert Opin. Biol. Ther. 13, 1207–1214 (2013).
Moran, G. W., Leslie, F. C. & McLaughlin, J. T. Crohn's disease affecting the small bowel is associated with reduced appetite and elevated levels of circulating gut peptides. Clin. Nutr. 32, 404–411 (2013).
Friedrich, M., Diegelmann, J., Schauber, J., Auernhammer, C. J. & Brand, S. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal Immunol. 8, 943–958 (2015).
Iannone, F. et al. Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun. Rev. 15, 447–450 (2016).
Versini, M., Jeandel, P.-Y., Rosenthal, E. & Shoenfeld, Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun. Rev. 13, 981–1000 (2014).
Hass, D. J., Brensinger, C. M., Lewis, J. D. & Lichtenstein, G. R. The impact of increased body mass index on the clinical course of Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 482–488 (2006).
Singh, S., Khera, R. & Sandborn, W. J. Obesity is associated with worse outcomes in hospitalized patients with inflammatory bowel diseases: a nationwide study. Am J Gastroenterol. 111, S271 (2016).
Erhayiem, B., Dhingsa, R., Hawkey, C. J. & Subramanian, V. Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn's disease. Clin. Gastroenterol. Hepatol. 9, 684–687. e1 (2011).
Li, Y. et al. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn's disease. Colorectal Dis. 17, 225–234 (2015).
Fitzmorris, P. S. et al. Impact of metabolic syndrome on the hospitalization rate of Crohn's disease patients seen at a tertiary care center: a retrospective cohort study. Digestion 91, 257–262 (2015).
Harper, J. W., Welch, M. P., Sinanan, M. N., Wahbeh, G. T. & Lee, S. D. Co-morbid diabetes in patients with Crohn's disease predicts a greater need for surgical intervention. Aliment. Pharmacol. Ther. 35, 126–132 (2012).
Dutton, G. R. et al. 25-year weight gain in a racially balanced sample of U.S. adults: The CARDIA study. Obesity. 24, 19620–1968 (2016).
Singh, S. et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 14, 1120–1129. e6 (2016).
Osterman, M. T. et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin. Gastroenterol. Hepatol. 12, 811–817. e3 (2014).
Singh, S. et al. Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin. Proc. 89, 1621–1635 (2014).
Bhalme, M., Sharma, A., Keld, R., Willert, R. & Campbell, S. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease? Eur. J. Gastroenterol. Hepatol. 25, 543–549 (2013).
Puig, L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J. Eur. Acad. Dermatol. Venereol. 25, 1007–1011 (2011).
Dotan, I. et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm. Bowel Dis. 20, 2247–2259 (2014).
Sharma, S. et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm. Bowel Dis. 21, 783–792 (2015).
Colombel, J. F. et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 12, 423–431. e1 (2014).
Xu, Z. H. et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int. J. Clin. Pharmacol. Ther. 48, 596–607 (2010).
Rosario, M. et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment. Pharmacol. Ther. 42, 188–202 (2015).
Brill, M. J. et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin. Pharmacokinet. 51, 277–304 (2012).
Harper, J. W., Sinanan, M. N. & Zisman, T. L. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 19, 2118–2124 (2013).
Bultman, E. et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment. Pharmacol. Ther. 35, 335–341 (2012).
Bond, A. et al. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. Eur. J. Gastroenterol. Hepatol. 28, 271–276 (2016).
Klaasen, R., Wijbrandts, C. A., Gerlag, D. M. & Tak, P. P. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 63, 359–364 (2011).
Gremese, E. et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 65, 94–100 (2013).
Eder, L., Thavaneswaran, A., Chandran, V., Cook, R. J. & Gladman, D. D. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann. Rheum. Dis. 74, 813–817 (2015).
Poon, S. S. et al. Body mass index and smoking affect thioguanine nucleotide levels in inflammatory bowel disease. J. Crohns Colitis 9, 640–646 (2015).
Boutros, M. & Maron, D. Inflammatory bowel disease in the obese patient. Clin. Colon Rectal Surg. 24, 244–252 (2011).
Makino, T., Shukla, P. J., Rubino, F. & Milsom, J. W. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection. Ann. Surg. 255, 228–236 (2012).
Hussan, H. et al. Morbid obesity is associated with increased mortality, surgical complications, and incremental health care utilization in the peri-operative period of colorectal cancer surgery. World J. Surg. 40, 987–994 (2016).
Jain, A., Limketkai, B. N. & Hutfless, S. The effect of obesity on post-surgical complications during hospitalizations for inflammatory bowel disease: a nationwide analysis. Gastroenterology 146, S595–S596 (2014).
Duchesne, J. C., Wang, Y. Z., Weintraub, S. L., Boyle, M. & Hunt, J. P. Stoma complications: a multivariate analysis. Am. Surg. 68, 961–966 (2002).
Beck, S. J. Stoma issues in the obese patient. Clin. Colon Rectal Surg. 24, 259–262 (2011).
Klos, C. L. et al. Obesity increases risk for pouch-related complications following restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). J. Gastrointest. Surg. 18, 573–579 (2014).
Kiran, R. P. et al. Complications and functional results after ileoanal pouch formation in obese patients. J. Gastrointest. Surg. 12, 668–674 (2008).
Stidham, R. W. et al. Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn's disease. Inflamm. Bowel Dis. 21, 1306–1313 (2015).
Ding, Z. et al. Association between high visceral fat area and postoperative complications in patients with Crohn's disease following primary surgery. Colorectal Dis. 18, 163–172 (2016).
Carucci, L. R. Imaging obese patients: problems and solutions. Abdom. Imaging 38, 630–646 (2013).
Upala, S. & Sanguankeo, A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int. J. Obes. 39, 1197–1202 (2015).
Di Minno, M. N. et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann. Rheum. Dis. 73, 1157–1162 (2014).
Colombo, F. et al. Bariatric surgery in patients with inflammatory bowel disease: an accessible path? Report of a case series and review of the literature. J. Crohns Colitis 9, 185–190 (2015).
Aminian, A. et al. Outcomes of bariatric surgery in patients with inflammatory bowel disease. Obes. Surg. 26, 1186–1190 (2016).
Johnston, B. C. et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 312, 923–933 (2014).
Khera, R. et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 315, 2424–2434 (2016).
Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76. (2011).
Takayanagi, Y. et al. Norepinephrine suppresses IFN-gamma and TNF-alpha production by murine intestinal intraepithelial lymphocytes via the beta(1) adrenoceptor. J. Neuroimmunol. 245, 66–74 (2012).
Smith, J. P. et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig. Dis. Sci. 56, 2088–2097 (2011).
Brustolim, D., Ribeiro- dos-Santos, R., Kast, R. E., Altschuler, E. L. & Soares, M. B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6, 903–907 (2006).
Kane, S., Altschuler, E. L. & Kast, R. E. Crohn's disease remission on bupropion. Gastroenterology 125, 1290 (2003).
Krane, M. K. et al. Does morbid obesity change outcomes after laparoscopic surgery for inflammatory bowel disease? Review of 626 consecutive cases. J. Am. Coll. Surg. 216, 986–996 (2013).
Causey, M. W. et al. The impact of obesity on outcomes following major surgery for Crohn's disease: an American College of Surgeons National Surgical Quality Improvement Program assessment. Dis. Colon Rectum 54, 1488–1495 (2011).
S.S. is supported by the NIH/National Library of Medicine training grant T15LM011271, the American College of Gastroenterology Junior Faculty Development Award and the Crohn's and Colitis Foundation of American Career Development Award. P.S.D. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases training grant 5T32DK007202. A.Z. has received support from NIH K08 DK102902, the American Association for the Study of Liver Diseases Liver Scholar Award, and the American Gastroenterological Association Microbiome Junior Investigator Research Award. The Authors thank L. J. Prokop, Senior Medical Librarian at Mayo Clinic, Rochester, USA, who assisted with a systematic literature review on this topic.
W.J.S. has received consulting fees from Abbvie, Janssen Biotech, Prometheus Laboratories and UCB Pharma, research grants from Abbvie, Janssen Pharmaceutical Research & Development and UCB Pharma, and payments for lectures or speakers bureau from Abbvie, Janssen Pharmaceutical Research & Development. S.S., P.S.D., A.Z. and S.R. declare no competing interests.
About this article
Cite this article
Singh, S., Dulai, P., Zarrinpar, A. et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol 14, 110–121 (2017). https://doi.org/10.1038/nrgastro.2016.181
Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review
Reumatología Clínica (English Edition) (2020)
Safety of bariatric surgery in patients with inflammatory bowel disease: A systematic review and meta‐analysis
Clinical Obesity (2020)
Scandinavian Journal of Gastroenterology (2020)
Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn’s Disease
Inflammatory Bowel Diseases (2020)
Visceral Adipose Tissue Derived Exosomes Exacerbate Colitis Severity via Pro-inflammatory MiRNAs in High Fat Diet Fed Mice
ACS Nano (2020)